The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Point-of-Care solution to facilitate clinicians in quick and effective decision making
AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
APAC to see a reduction in imported surgical robotics
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Subscribe To Our Newsletter & Stay Updated
